Coronavirus disease-2019 (COVID-19), a viral respiratory illness caused
by the severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2), may
predispose patients to thrombotic disease, both in the venous and
arterial circulations, because of excessive inflammation, platelet
activation, endothelial dysfunction, and stasis. In addition, many
patients receiving antithrombotic therapy for thrombotic disease may
develop COVID-19, which can have implications for choice, dosing, and
laboratory monitoring of antithrombotic therapy. Moreover, during a time
with much focus on COVID-19, it is critical to consider how to optimize
the available technology to care for patients without COVID-19 who have
thrombotic disease. Herein, the authors review the current understanding
of the pathogenesis, epidemiology, management, and outcomes of patients
with COVID-19 who develop venous or arterial thrombosis, of those with
pre-existing thrombotic disease who develop COVID-19, or those who need
prevention or care for their thrombotic disease during the COVID-19
pandemic. (J Am Coll Cardiol 2020;75:2950-73) (c) 2020 by the American
College of Cardiology Foundation